Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 905677 in Advanced Solid Tumours
NCT03604445Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of BI 905677 in solid tumor (advanced stage) (9 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Participants With Dose Limiting Toxicities and Number of Patients Experiencing Adverse Events up to 36 weeks. Started Aug 2018; status: terminated.
02
Drugs
BI 905677
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03604445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604445.